Sfoglia per AUTORE
FALCONE AP
Collezione AOU Città della Salute di Torino

  

Items : 13

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients. in European journal of haematology / Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19.

2025
AOU Città della Salute di Torino
AOU Novara

Quaresima M; Barbieri E; D'Arrigo G; Reddiconto G; Tripepi G; Morè S; Sica A; Mele G; Falcone AP; Mancuso K; Cangialosi C; Farina G; Vincelli ID; Paris L; Mina R; Fazio F; Bruzzese A; Vigna E; Della Pepa R; Mele A; Musso M; Palmieri S; Zamagni E; Conticello C; Bolli N; Pettine L; Petrucci MT; De Magistris C; Lotti F; et alii...

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI). in Cancer / Cancer. 2025 Apr 1;131(7):e35801. doi: 10.1002/cncr.35801.

2025
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Tomassetti S; Lunghi F; Cavazzini F; Pocali B; Binotto G; Tiribelli M; Brociner M; Vallisa D; Falcone AP; Caocci G; De Stefano V; Gardellini A; Elli EM; Bonifacio M; Farina G; Micucci G; Benevolo G; Morsia E; Pastore D; Polizzi V; Tafuri A; Urbano T; Liberati AM; Itri F; Ditonno P; Carli G; Langella M; Ricco A; Impera S; et alii...

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials. in Frontiers in oncology / Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022.

2022
AOU Città della Salute di Torino

De Stefano V; Musto P; Gamberi B; Curci P; Mimmi S; Rizzello I; Iaccino E; Barone M; Farina G; Reddiconto G; Cangialosi C; Falcone AP; Frigeri F; Tripepi G; Ballanti S; Cascavilla N; Garibaldi B; Rocchi S; Pantani L; Mele A; Botta C; Mendicino F; Bruzzese A; Martino EA; Vigna E; Mele G; Vincelli ID; Tacchetti P; Catalano L; et alii...

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. in Blood cancer journal / Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5.

2021
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino

Larocca A; Corradini P; Monaco F; Boccadoro M; Ballanti S; Offidani M; De Paoli L; De Sabbata G; Aquino S; Paris L; Grasso M; Belotti A; Cellini C; Tacchetti P; Zambello R; Musolino C; Cea M; Bonello F; Rota-Scalabrini D; Patriarca F; Capra A; Petrucci MT; Ciccone G; Liberati AM; Pescosta N; Bringhen S; Falcone AP; Mina R;

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. in Haematologica / Haematologica. 2020 Apr;105(4):1074-1080. doi: 10.3324/haematol.2019.220657. Epub 2019 Jun 27.

2020
AOU Città della Salute di Torino

Palumbo A; De Paoli L; Romano A; Zambello R; Falcone AP; Giuliani N; Paris L; Fraticelli V; Amico V; Musto P; Bernardini A; Cangiolosi C; Innao V; Oddolo D; Benevolo G; Spada S; Evangelista A; Patriarca F; Ledda A; Liberati AM; Offidani M; Mina R; Larocca A; Montefusco V; Hájek R; Boccadoro M; Bringhen S;

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. in Journal of hematology & oncology / J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ria R; Boccadoro M; Vacca A; Dammacco F; Petrucci MT; Musto P; Montefusco V; Rizzo M; Falcone AP; Grasso M; Gottardi D; Leonardi G; Baldini L; Benevolo G; Callea V; Patriarca F; Guglielmelli T; Nozzoli C; Larocca A; Offidani M; De Paoli L; Martino E; Bringhen S; Palumbo A; Omedè P; Giuliani N; Saltarella I; Terragna C; Morabito F; et alii...

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 2

2018
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Bringhen S; Boccadoro M; Spencer A; Hájek R; Nagler A; Calafiore V; Falcone AP; Palumbo A; Benevolo G; Zambello R; Mannina D; Gamberi B; Baldini L; Guglielmelli T; Musto P; Malfitano A; Pescosta N; Ria R; De Paoli L; Cerrato C; Patriarca F; Spada S; Corradini P; Mina R; Petrucci MT; Mina R; Petrucci MT; Corradini P; Spada S; et alii...

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. in Leukemia / Leukemia. 2017 Aug;31(8):1727-1734. doi: 10.1038/leu.2016.381. Epub 2016 Dec 23.

2017
AOU Città della Salute di Torino

Nagler A; Patriarca F; Caravita T; Falcone AP; Malfitano A; Cafro AM; Liberati AM; Troia R; Omedé P; Offidani M; Carella AM; Salvini M; Ria R; Campbell P; Spada S; Evangelista A; Catalano L; Musto P; Conticello C; Montefusco V; Petrucci MT; Oliva S; Gay F; Spencer A; Hajek R; Palumbo A; Boccadoro M;

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. in Blood / Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4.

2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Palumbo A; Boccadoro M; Hajek R; Montefusco V; Guglielmelli T; Ledda A; Liberati AM; Ruggeri M; Zambello R; Maisnar V; Conticello C; Pulini S; Ciccone G; Bernardini A; Giuliani N; Musolino C; Gentili S; Pietrantuono G; Falcone AP; De Paoli L; Mina R; Patriarca F; Benevolo G; Offidani M; Bringhen S; Magarotto V;

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. in Leukemia / Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

2016
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Palumbo A; Sonneveld P; Offidani M; Boccadoro M; Musolino C; De Paoli L; Conticello C; Nozzoli C; Aghemo E; Derudas D; Genuardi M; Guglielmelli T; Carella AM; Ponticelli E; Spada S; Vincelli ID; De Rosa L; Omedé P; Morabito F; Montefusco V; Passera R; Benevolo G; Liberati AM; Falcone AP; Caravita T; Villani O; Oliva S; Petrucci MT; Bringhen S; et alii...

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. in Leukemia / Leukemia. 2015 Mar;29(3):689-95. doi: 10.1038/leu.2014.219. Epub 2014 Jul 16.

2015
AOU Città della Salute di Torino

Terragna C; Musto P; Oliva S; Pisani F; Falcone AP; Pregno P; Crippa C; De Rosa L; Callea V; Carovita T; Liberati AM; Cangialosi C; Guglielmelli T; Rossini F; Grasso M; Caltagirone S; Urbano M; Genuardi E; Cavallo F; Ladetto M; Drandi D; Ferrero S; Passera R; Boccadoro M; Palumbo A;

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Ria R; Offidani M; Gaidano G; Passera R; Nozzoli C; Guglielmelli T; Mina R; Morabito F; Marasca R; Omedé P; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Palumbo A; Petrucci MT; Musto P; Boccadoro M; et alii...

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. in Haematologica / Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.

2013
AOU Città della Salute di Torino

Bringhen S; Mateos MV; Zweegman S; Larocca A; Falcone AP; Oriol A; Rossi D; Cavalli M; Wijermans P; Ria R; Offidani M; Lahuerta JJ; Liberati AM; Mina R; Callea V; Schaafsma M; Cerrato C; Marasca R; Franceschini L; Evangelista A; Teruel AI; van der Holt B; Montefusco V; Ciccone G; Boccadoro M; San Miguel J; Sonneveld P; Palumbo A;